GO:0102266 tRNA-dihydrouridine20a synthase activity

GO:0102266, tRNA-dihydrouridine20a synthase activity, is a molecular function that catalyzes the NAD(P)-dependent reduction of a uracil20a residue in tRNA to 5,6-dihydrouracil20a. This modification expands the chemical repertoire of tRNA and contributes to the structural and functional plasticity of the translation machinery. Dihydrouridine is one of the most prevalent modified nucleosides in tRNA and is particularly enriched in the D-loop, where it influences local RNA flexibility and tRNA folding. Because tRNA modifications are emerging as dynamic regulators of gene expression, understanding GO:0102266 is important for researchers studying translation, metabolism, and disease. The reaction is reversible and redox-coupled, linking tRNA modification directly to cellular NAD(P)/NAD(P)H balance. This makes the enzyme a potential node integrating metabolic state with protein synthesis. In this article, we summarize the definition, mechanism, key genes, disease links, and experimental strategies for studying GO:0102266, with a focus on CRISPR-based models and functional genomics.

GO:0102266 is defined as the catalysis of the reaction: a 5,6-dihydrouracil20a in tRNA + NAD(P) = H+ + a uracil20a in tRNA + NAD(P)H. In other words, it is the enzyme activity that reduces a specific uracil base at position 20a of a tRNA molecule to dihydrouracil, using NAD(P) as the electron donor. This is a post-transcriptional modification reaction that occurs on the tRNA polynucleotide chain rather than on free nucleotides. The activity is associated with dihydrouridine synthase (Dus) family enzymes, which typically contain a flavin mononucleotide (FMN) cofactor and use NAD(P)H as a reductant. The reaction is reversible, and the equilibrium can be influenced by the cellular redox state.

GO:0102266 is important because dihydrouridine is a abundant and conserved tRNA modification that affects tRNA folding, stability, and decoding capacity. By coupling tRNA modification to NAD(P) redox chemistry, this activity provides a direct link between cellular metabolism and translation. Dysregulation of tRNA modification enzymes has been implicated in a growing number of human diseases, including cancer and mitochondrial disorders. Therefore, understanding GO:0102266 at the molecular, cellular, and organismal levels can reveal new therapeutic targets and biomarkers.

The following genes and proteins are directly or functionally associated with tRNA-dihydrouridine20a synthase activity and related tRNA modification pathways.

The activity of GO:0102266 is likely regulated at multiple levels, including enzyme expression, cofactor availability, and cellular redox state. Because the reaction uses NAD(P) as a co-substrate, fluctuations in NAD(P)/NAD(P)H ratio can directly influence the equilibrium of the reaction. Metabolic pathways that consume or produce NAD(P)H, such as glycolysis and oxidative phosphorylation, may therefore modulate dihydrouridine levels. Additionally, stress-responsive signaling pathways such as the integrated stress response (ISR) and mTOR signaling can affect translation and tRNA modification indirectly. However, direct evidence for specific regulators of GO:0102266 in human cells remains limited and requires further study.

Altered tRNA modification, including dihydrouridine, has been observed in various cancers. DUS enzymes can influence translation of oncogenes and tumor suppressors, and their dysregulation may contribute to tumor progression. Targeting GO:0102266-related pathways is being explored as a therapeutic strategy.

Mitochondrial tRNAs are heavily modified, and defects in modification enzymes can cause mitochondrial dysfunction. Mutations in DUS genes have been linked to mitochondrial disease phenotypes. Studying GO:0102266 in mitochondrial tRNA context may reveal new disease mechanisms.

tRNA modification defects are increasingly recognized in neurological disorders such as intellectual disability and neurodegeneration. Dihydrouridine synthases may play roles in neuronal translation and stress responses. Further research is needed to establish causal links.

Bacterial Dus enzymes are essential for tRNA modification and are potential antibiotic targets. Inhibiting GO:0102266 activity could impair bacterial translation and growth. This makes it an attractive target for antimicrobial development.

Ribo-seq measures ribosome occupancy and translation efficiency, which can be affected by tRNA modification status. tRNA sequencing methods such as DM-tRNA-seq or Nanopore can directly detect dihydrouridine modifications. Combining these with CRISPR knockouts of DUS genes allows functional dissection of GO:0102266.

Mass spectrometry can quantify dihydrouridine levels in purified tRNA. Proteomics can identify interacting proteins and post-translational modifications of Dus enzymes. These approaches provide biochemical validation of GO:0102266 activity.

Genome-wide CRISPR knockout screens can identify genes that are essential in the presence or absence of DUS enzymes. Such screens can reveal synthetic lethal interactions and pathways that buffer tRNA modification defects. This is a powerful approach to uncover disease-relevant mechanisms.

Fluorescent tRNA reporters can visualize tRNA localization and modification in live cells. Reporter assays can measure translation of specific codons that depend on dihydrouridine-containing tRNAs. These methods complement biochemical and sequencing approaches.

Researchers studying tRNA-dihydrouridine20a synthase activity-related genes often need to determine whether a candidate gene is causally involved in tRNA modification, translation, or disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such functional studies.

GO:0102266, tRNA-dihydrouridine20a synthase activity, represents a critical link between tRNA modification, translation, and cellular metabolism. Its reversible, NAD(P)-dependent chemistry allows cells to dynamically adjust tRNA structure in response to metabolic cues. Dysregulation of this activity has been implicated in cancer, mitochondrial disease, and other disorders, making it a compelling target for further research. By combining CRISPR-based models with advanced sequencing and proteomics, researchers can uncover the precise roles of DUS enzymes in health and disease.